Care and Use of Laboratory Animals. The Recipient must comply with the care and use of laboratory animal standards pursuant to the following:
A. Animal Welfare Act, 7 USC 2131, as implemented at 9 CFR, Sub Chapter A, Parts 1-4; and
B. Marine Mammal Protection Act, 16 USC 1361-1407.
Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources, National Research Council.
Care and Use of Laboratory Animals. The Contractor shall maintain such assurance for the duration of this contract, and any subcontractors performing work under this contract involving the use of animals shall also obtain and maintain an approved Animal Welfare Assurance.
Care and Use of Laboratory Animals. The Contractor shall maintain such assurance for the duration of this contract, and any subcontractors performing work under this contract involving the use of animals shall also obtain and maintain an approved Animal Welfare Assurance. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. All research involving live, vertebrate animals shall be conducted in accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals. This policy may be accessed at xxxx://xxxxxx0.xxx.xxx/grants/olaw/references/phspo1.htm
Care and Use of Laboratory Animals the Federation of Animal Science Societies Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching; any additional Requirements set forth in DHS Directive 026-01 regarding the Care and Use of Animals in Research; Requirements set forth in 45 CFR Part 46, Subparts A-D; DHS Directive 026-04 entitled “Protection of Human Subjects” and any related DHS policies and instructions. Subrecipient shall not initiate any activities contemplated under this Section or execute modifications to any such approved activities until all documentation and forms required by the Grantor pursuant to Requirements set forth in this Section is duly submitted to and approved by the Grantor.
Care and Use of Laboratory Animals. All experiments were approved by the Emory Institutional Care and Use Committee. Drugs used in this study were: reboxetine (Pfizer, Groton, CT), desipramine (Sigma- Xxxxxxx, St. Xxxxx, MO), imipramine (Sigma-Xxxxxxx), bupropion (Sigma-Xxxxxxx), GBR12909 (Sigma-Xxxxxxx) and venlafaxine (Wyeth, Monmouth Junction, MJ). Drugs were administered acutely via i.p. injection or chronically via Alzet® osmotic minipumps (Model #2004, 0.25 l/hr, 28 d; Durect, Cupertino, CA). For chronic administration, antidepressants were dissolved in either 0.9% sterile saline (reboxetine, 20 mg/kg/d; imipramine, 120 mg/kg/d; venlafaxine, 20 mg/kg/d; bupropion, 40 mg/kg/d) or an aqueous solution containing 50% ethanol and 0.9% sterile saline (desipramine, 20 mg/kg/d), and loaded into pumps. Doses were chosen to achieve serum levels that fell within or very close to human therapeutic range (Xxxxx et al., 2006). Minipumps containing 0.9% sterile saline or a 50% ethanol/0.9% sterile saline aqueous solution were used as vehicle controls. All pumps were placed in a sterile 37C saline bath for 1 day before implantation. Mice were anesthetized with isoflurane and minipumps were implanted in the intraperitoneal cavity. Buprenorphine (2.5 mg/kg, s.c.) was given immediately following surgery for pain management. For acute administration, all antidepressants were dissolved in vehicle (0.9% sterile saline) except for GBR12909 (1.5% DMSO, 0.9% sterile saline) and injected i.p. as a bolus (10 ml/kg) using the same doses as for the chronic paradigm. The exceptions were (1) imipramine, which caused profound ataxia and sedation when 120 mg/kg was injected acutely, so 20 mg/kg was used instead, and (2) GBR12909 (20 mg/kg), which is not used clinically as an antidepressant and was not tested in the chronic experiment. For acute experiments in a novel environment, drugs were injected i.p. 30 minutes prior to placement in unfamiliar transparent plexiglass cages (40 x 20 x 20 cm) situated in racks with 7 infrared photobeams spaced 5 cm apart, each end beam 5 cm from the cage wall (San Diego Instruments Inc., LaJolla, CA). Activity xxxxxxxx were connected via an interface to a computer, and ambulations (consecutive beam breaks) were recorded. Testing began between 0900-1000 and continued for 2 hours. For chronic experiments in a novel environment, mice were tested, as described above, 18-20 days after minipump implantation. For chronic experiments in a familiar environment, mice were housed with food an...
